NASDAQ:AKER - Akers Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.39 +0.03 (+2.21 %)
(As of 01/22/2019 03:35 AM ET)
Previous Close$1.36
Today's Range$1.32 - $1.40
52-Week Range$0.57 - $7.84
Volume200,912 shs
Average Volume539,376 shs
Market Capitalization$17.34 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.93
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ‘Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKER
CUSIPN/A
Phone856-848-8698

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.93 million
Book Value$1.05 per share

Profitability

Net Income$-7,360,000.00
Net Margins-346.69%

Miscellaneous

Employees32
Market Cap$17.34 million
OptionableNot Optionable

Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

How were Akers Biosciences' earnings last quarter?

Akers Biosciences Inc (NASDAQ:AKER) posted its quarterly earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter. Akers Biosciences had a negative return on equity of 107.79% and a negative net margin of 346.69%. View Akers Biosciences' Earnings History.

When is Akers Biosciences' next earnings date?

Akers Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for Akers Biosciences.

Has Akers Biosciences been receiving favorable news coverage?

Media stories about AKER stock have been trending very positive on Tuesday, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Akers Biosciences earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are some of Akers Biosciences' key competitors?

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the folowing people:
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 63)
  • Mr. Howard R. Yeaton Jr., CPA, CEO & Interim CFO (Age 64)
  • Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial Operations
  • Ms. Pamela E. Hibler, VP of Sales & Distribution
  • Mr. Richard E. McKee, VP of Engineering

Who are Akers Biosciences' major shareholders?

Akers Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.21%). View Institutional Ownership Trends for Akers Biosciences.

Which major investors are buying Akers Biosciences stock?

AKER stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Akers Biosciences.

How do I buy shares of Akers Biosciences?

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $1.39.

How big of a company is Akers Biosciences?

Akers Biosciences has a market capitalization of $17.34 million and generates $3.93 million in revenue each year. Akers Biosciences employs 32 workers across the globe.

What is Akers Biosciences' official website?

The official website for Akers Biosciences is http://www.akerslaboratories.com.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-8698 or via email at [email protected]


MarketBeat Community Rating for Akers Biosciences (NASDAQ AKER)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe AKER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel